HK1245331A1 - 基於李斯特菌的疫苗與抗ox40或抗gitr抗體的組合 - Google Patents
基於李斯特菌的疫苗與抗ox40或抗gitr抗體的組合Info
- Publication number
- HK1245331A1 HK1245331A1 HK18104871.6A HK18104871A HK1245331A1 HK 1245331 A1 HK1245331 A1 HK 1245331A1 HK 18104871 A HK18104871 A HK 18104871A HK 1245331 A1 HK1245331 A1 HK 1245331A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- listeria
- combination
- based vaccine
- gitr antibodies
- gitr
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462094472P | 2014-12-19 | 2014-12-19 | |
US201462094349P | 2014-12-19 | 2014-12-19 | |
US201562147463P | 2015-04-14 | 2015-04-14 | |
US201562262896P | 2015-12-03 | 2015-12-03 | |
PCT/US2015/066896 WO2016100929A1 (en) | 2014-12-19 | 2015-12-18 | Combination of listeria-based vaccine with anti-ox40 or anti-gitr antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1245331A1 true HK1245331A1 (zh) | 2018-08-24 |
Family
ID=56127737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18104871.6A HK1245331A1 (zh) | 2014-12-19 | 2018-04-13 | 基於李斯特菌的疫苗與抗ox40或抗gitr抗體的組合 |
HK18105357.6A HK1246341A1 (zh) | 2014-12-19 | 2018-04-25 | 採用重組李斯特氏菌株的聯合治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18105357.6A HK1246341A1 (zh) | 2014-12-19 | 2018-04-25 | 採用重組李斯特氏菌株的聯合治療 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20170368157A1 (zh) |
EP (2) | EP3234106A4 (zh) |
JP (2) | JP2018501244A (zh) |
KR (2) | KR20170092626A (zh) |
CN (2) | CN107427565A (zh) |
AU (2) | AU2015364255A1 (zh) |
CA (2) | CA2971455A1 (zh) |
HK (2) | HK1245331A1 (zh) |
IL (2) | IL252680A0 (zh) |
MA (2) | MA41217A (zh) |
MX (2) | MX2017008187A (zh) |
SG (2) | SG11201704662SA (zh) |
TW (2) | TW201636360A (zh) |
WO (2) | WO2016100929A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
AU2013232291B8 (en) | 2012-03-12 | 2016-07-21 | Advaxis, Inc. | Suppressor cell function inhibition following listeria vaccine treatment |
CA2910278C (en) | 2013-05-02 | 2021-09-28 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
CN106456726A (zh) | 2014-02-18 | 2017-02-22 | 阿德瓦希斯公司 | 生物标志物导向的多靶点免疫治疗 |
CN106459887A (zh) | 2014-04-24 | 2017-02-22 | 阿德瓦希斯公司 | 重组李斯特菌疫苗菌株及其制备方法 |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
WO2016183361A1 (en) * | 2015-05-13 | 2016-11-17 | Advaxis, Inc. | Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof |
CA3008641A1 (en) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
SG10201913306WA (en) | 2016-11-01 | 2020-02-27 | Anaptysbio Inc | Antibodies directed against programmed death- 1 (pd-1) |
MA46721A (fr) * | 2016-11-07 | 2019-09-11 | Advaxis Inc | Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 |
SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
KR102606252B1 (ko) | 2017-01-09 | 2023-11-23 | 테사로, 인코포레이티드 | 항-pd-1 항체로 암을 치료하는 방법 |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
CN109136275B (zh) | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化gitr基因改造动物模型的制备方法及应用 |
CA3075849A1 (en) | 2017-09-19 | 2019-03-28 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
WO2019104203A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
AU2019231783B2 (en) * | 2018-03-09 | 2023-11-16 | Advaxis, Inc. | Compositions and methods for evaluating attenuation and infectivity of Listeria strains |
CN111918873A (zh) | 2018-03-27 | 2020-11-10 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
CN110408634B (zh) | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
CN110579608B (zh) * | 2018-06-11 | 2022-07-08 | 苏州若泰医药科技有限公司 | 一种筛选高表达外源蛋白的非整合减毒李斯特菌菌株的方法 |
US10925947B2 (en) * | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
CN111979162B (zh) * | 2019-05-22 | 2024-02-13 | 上海市公共卫生临床中心 | 重组卡介苗菌株、其制备方法和用途 |
EP3973274A1 (en) | 2019-05-23 | 2022-03-30 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
CN114502587A (zh) * | 2019-07-30 | 2022-05-13 | 普瑞文森生物有限公司 | 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物 |
WO2021098749A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in combination with radiation |
BR112022026509A2 (pt) | 2020-06-23 | 2023-03-07 | Univ Colorado Regents | Métodos para diagnosticar patógenos respiratórios e prever resultados relacionados à covid-19 |
KR20230080460A (ko) | 2020-10-05 | 2023-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질을 농축시키는 방법 |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
CN114736295B (zh) * | 2022-06-14 | 2022-08-09 | 北京科跃中楷生物技术有限公司 | 一种辣根过氧化物酶标记抗体及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7635479B2 (en) * | 2000-03-29 | 2009-12-22 | The Trustees Of The University Of Pennsylvania | Composition and methods for enhancing immunogenecity of antigens |
US10106619B2 (en) * | 2006-10-04 | 2018-10-23 | La Jolla Institute For Allergy And Immunology | Virus vaccination and treatment methods with OX40 agonist compositions |
EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
CN101214372A (zh) * | 2008-01-04 | 2008-07-09 | 中国人民解放军第四军医大学 | 一种体内诱导出针对TNF-α分子的自身抗体的蛋白疫苗的构建方法 |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US20120135033A1 (en) * | 2008-05-19 | 2012-05-31 | Anu Wallecha | Multiple delivery system for heterologous antigens |
WO2011100754A1 (en) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Live listeria-based vaccines for central nervous system therapy |
US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
US20140356930A1 (en) * | 2013-06-03 | 2014-12-04 | Panacea Pharmaceuticals | Immune system enhancing immunotherapy for the treatment of cancer |
-
2015
- 2015-12-17 MA MA041217A patent/MA41217A/fr unknown
- 2015-12-17 MA MA041218A patent/MA41218A/fr unknown
- 2015-12-18 MX MX2017008187A patent/MX2017008187A/es unknown
- 2015-12-18 US US15/533,645 patent/US20170368157A1/en not_active Abandoned
- 2015-12-18 CA CA2971455A patent/CA2971455A1/en not_active Abandoned
- 2015-12-18 MX MX2017008173A patent/MX2017008173A/es unknown
- 2015-12-18 WO PCT/US2015/066896 patent/WO2016100929A1/en active Application Filing
- 2015-12-18 KR KR1020177018025A patent/KR20170092626A/ko unknown
- 2015-12-18 CA CA2971220A patent/CA2971220A1/en not_active Abandoned
- 2015-12-18 JP JP2017532925A patent/JP2018501244A/ja active Pending
- 2015-12-18 US US15/534,910 patent/US20180153974A1/en not_active Abandoned
- 2015-12-18 SG SG11201704662SA patent/SG11201704662SA/en unknown
- 2015-12-18 EP EP15871241.4A patent/EP3234106A4/en not_active Withdrawn
- 2015-12-18 WO PCT/US2015/066885 patent/WO2016100924A1/en active Application Filing
- 2015-12-18 SG SG11201704599PA patent/SG11201704599PA/en unknown
- 2015-12-18 KR KR1020177019838A patent/KR20170096012A/ko unknown
- 2015-12-18 CN CN201580069609.7A patent/CN107427565A/zh active Pending
- 2015-12-18 AU AU2015364255A patent/AU2015364255A1/en not_active Abandoned
- 2015-12-18 TW TW104142874A patent/TW201636360A/zh unknown
- 2015-12-18 EP EP15871237.2A patent/EP3234148A4/en not_active Withdrawn
- 2015-12-18 JP JP2017532905A patent/JP2018501243A/ja active Pending
- 2015-12-18 CN CN201580074503.6A patent/CN107206060A/zh active Pending
- 2015-12-18 TW TW104142875A patent/TW201639594A/zh unknown
- 2015-12-18 AU AU2015364260A patent/AU2015364260A1/en not_active Abandoned
-
2017
- 2017-06-05 IL IL252680A patent/IL252680A0/en unknown
- 2017-06-07 IL IL252743A patent/IL252743A0/en unknown
-
2018
- 2018-04-13 HK HK18104871.6A patent/HK1245331A1/zh unknown
- 2018-04-25 HK HK18105357.6A patent/HK1246341A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016100924A1 (en) | 2016-06-23 |
KR20170096012A (ko) | 2017-08-23 |
SG11201704662SA (en) | 2017-07-28 |
US20180153974A1 (en) | 2018-06-07 |
IL252680A0 (en) | 2017-08-31 |
MX2017008173A (es) | 2017-09-18 |
TW201639594A (zh) | 2016-11-16 |
AU2015364255A1 (en) | 2017-07-20 |
CN107427565A (zh) | 2017-12-01 |
HK1246341A1 (zh) | 2018-09-07 |
TW201636360A (zh) | 2016-10-16 |
EP3234106A1 (en) | 2017-10-25 |
MX2017008187A (es) | 2017-09-13 |
EP3234106A4 (en) | 2018-07-18 |
WO2016100929A1 (en) | 2016-06-23 |
MA41218A (fr) | 2017-10-24 |
CA2971220A1 (en) | 2016-06-23 |
KR20170092626A (ko) | 2017-08-11 |
CN107206060A (zh) | 2017-09-26 |
CA2971455A1 (en) | 2016-06-23 |
EP3234148A1 (en) | 2017-10-25 |
EP3234148A4 (en) | 2018-10-17 |
IL252743A0 (en) | 2017-08-31 |
JP2018501244A (ja) | 2018-01-18 |
MA41217A (fr) | 2017-10-24 |
JP2018501243A (ja) | 2018-01-18 |
US20170368157A1 (en) | 2017-12-28 |
SG11201704599PA (en) | 2017-07-28 |
AU2015364260A1 (en) | 2017-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1245331A1 (zh) | 基於李斯特菌的疫苗與抗ox40或抗gitr抗體的組合 | |
IL304178A (en) | Anti-gitr antibodies and methods of using them | |
HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
ZA201606630B (en) | Anti-ox40 antibodies and methods of use | |
IL251537A0 (en) | Human anti-ox40 antibodies and their uses | |
HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
RS59664B1 (sr) | Anti-tim3 antitela i postupci upotrebe | |
DK3110843T3 (da) | Kombinationsterapier med anti-cd38-antistoffer | |
IL284291A (en) | Anti-acth antibodies from humans and their use | |
IL248399A0 (en) | New anti-43rnf antibodies and methods of use | |
ZA201701674B (en) | Novel anti-mfi2 antibodies and methods of use | |
IL247754A0 (en) | Antibodies against mcam and related methods of use | |
PT3101132T (pt) | Anticorpo humano anti-transtirretina | |
HK1244445A1 (zh) | 使用抗-ang2抗體的方法 | |
IL248697A0 (en) | Methods for purifying antibodies | |
PL3180356T3 (pl) | Ludzkie przeciwciało anty-fgfr4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CORR | Corrigendum |
Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20180824: (54) COMBINATION OF LISTERIA-BASED VACCINE WITH ANTI-OX40 OR ANTI-GITR ANTIBODIES |